

# Aurora Cannabis Inc

16:24 05 Nov 2019

## Cantor Fitzgerald: Don't give up on Canadian cannabis companies just yet

The grass is going to get greener for Canadian cannabis producers, say analysts at Cantor Fitzgerald. It's only a matter of time.

Valuations are at two-year lows, the firm said in a research note on Monday, and positive catalysts outweigh negative ones over the next year.

One such catalyst is the anticipated continued growth in the recreational cannabis sector. The recreational market in Canada is 12 times smaller than the market in Colorado, which analyst Pablo Zuanic said is encouraging given the constraints the sector has faced.

### READ: Israeli cannabis companies flower on the Canadian Securities Exchange

For instance, only dried flower and oils were permitted in the first year of legalization, while marketing visuals were restricted and many dispensary openings were delayed.

Recreational cannabis sales hit C\$127 million in July, and at the end of August, sales showed 50% growth quarter over quarter. All told, the firm expects the Canadian recreational market to be worth C\$4.5 billion by 2022.

To that end, Cantor Fitzgerald initiated coverage on six Canadian companies:

- Aurora Cannabis Inc (TSE:ACB) was rated Neutral with a price target of C\$5.10, implying 8.7% upside
- Aphria Inc (TSE:APHA) was rated Overweight with a target of C\$10.40, implying 52% upside
- HEXO Corp (TSE:HEXO) (NYSE:HEXO) was rated Underweight with a target of C\$2.40, implying 16% downside
- Organigram Holdings Inc (TSE:OGI) was rated Overweight with a target of C\$17.10, implying 283% upside
- Tilray Inc (NASDAQ:TLRY) was rated Neutral with a target of US\$20, implying 7.5% downside
- Canopy Growth Corporation (TSE:WEED) (NYSE:CGC) was rated Neutral with a target of C\$27, implying 4.2% upside
- Aurora and Canopy, though neutral, were placed in the firm's "positive watch" category.

Medical cannabis, meanwhile, could also serve as a catalyst outside of Canada.

Germany, a significant medical cannabis player, is projected to see per capita medical marijuana spending increase to \$12 from \$3 this year, according to BDS Analytics. For comparison, Colorado spends \$58 per capita, leaving a wide window open for growth.

Additionally, even though the ratings vary, the analyst note emphasized the promise of Canadian legacy producers as a

**Price:** 3.21

**Market Cap:** \$3.37 billion

### 1 Year Share Price Graph



December 2018 June 2019 December 20

### Share Information

**Code:** ACB

**Listing:** TSX

**52 week High Low**  
13.67 2.82

**Sector:** Cannabis

**Website:** auroramj.com

### Company Synopsis:

*A community minded medical cannabis company based in Vancouver, British Columbia.*

action@proactiveinvestors.com

whole.

Aphria and Organigram, the two Overweights, saw shares grow in Toronto by 0.4% to C\$6.76 and 5.5% to C\$4.57, respectively.

Contact Andrew Kessel at [andrew.kessel@proactiveinvestors.com](mailto:andrew.kessel@proactiveinvestors.com)

Follow him on Twitter @andrew\_kessel

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.